GlassScriptPhysician profile
Susan Younger
NPI 1598971830
$7,772.59
in general payments reported to CMS, 2019-2025
27 companies · $963 in 2025
The $963 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $616 · 2021: $1,575 · 2022: $1,239 · 2023: $1,339 · 2024: $805 · 2025: $963.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,106.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,480.79 | 2021-2025 | Vraylar |
| Takeda Pharmaceuticals U.S.A., INC. | $1,007.40 | 2019-2025 | Trintellix, Iclusig |
| Otsuka America Pharmaceutical, INC. | $981.98 | 2019-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $685.14 | 2019-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $355.36 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $344.87 | 2019-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $318.38 | 2022-2025 | Sunosi, Auvelity |
| Allergan, INC. | $285.69 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $284.58 | 2019-2023 | Spravato |
| Lundbeck LLC | $282.91 | 2019-2024 | Rexulti |
| Eisai INC. | $228.94 | 2020-2021 | |
| Ironshore Pharmaceuticals INC. | $228.60 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $220.41 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $187.17 | 2022-2024 | Austedo, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $172.40 | 2021-2023 | Caplyta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $152.63 | 2025 | Cobenfy |
| Collegium Pharmaceutical, INC. | $138.49 | 2025 | Jornay Pm |
| Neurocrine Biosciences, INC. | $137.76 | 2021-2025 | Ingrezza |
| Merck Sharp & Dohme LLC | $122.39 | 2019-2023 | Belsomra |
| Shire North American Group INC | $30.50 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.41 | 2019 | |
| Alfasigma USA, INC. | $22.84 | 2020 | |
| Idorsia Pharmaceuticals US INC | $18.25 | 2023 | Quviviq |
| Biogen, INC. | $17.62 | 2021 | |
| Adlon Therapeutics L.P. | $13.99 | 2020 | |
| Avanir Pharmaceuticals, INC. | $13.97 | 2021 | |
| Bausch Health US, LLC | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Younger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.